MELBOURNE, March 14, 2026, 10:01 AEDT
CSL Limited locked in the Australian dollar value of its interim dividend and kept buying back stock, but the moves did little to shift sentiment around the biotech’s shares. CSL closed Friday at A$141.03 after touching A$139.22, the bottom of its 52-week range. 1
That matters because investors are still trying to decide whether February’s profit shock and chief executive change marked the low point or the start of a longer reset. CSL shares have fallen 43.6% over the past year after the company reported an 81% drop in first-half profit, hurt by weaker sales of blood-plasma products and vaccines, one-off charges and the abrupt exit of Chief Executive Paul McKenzie; the stock fell to its lowest since 2018 after that result. 2
The latest buyback notice showed CSL repurchased 83,264 shares on Thursday for A$11.77 million. Before that session, the company had already bought back 4,233,728 shares under an on-market programme it said can reach US$750 million. 3
A separate filing set the Australian dollar equivalent of the interim dividend, first announced with half-year results, at A$1.809829 a share for holders with an Australian registered address. CSL said the payout is based on the March 11 record date and is due on April 9. 1
Interim chief Gordon Naylor has tried to strike a harder line. “I’m not prepared to accept that we can’t do better,” he said on the February analyst call, adding that the blood-plasma business remained “where the greatest opportunity lies”. 4
Morningstar analyst Shane Ponraj said on March 11 that CSL’s weaker plasma result pointed to more structural pressure than a short-term wobble. He cut his fair value estimate by 22% to A$210 and wrote that “competitors willing to sign lower-margin contracts” could force CSL to be more flexible in competitive bidding. 5
Ponraj also sketched the competitive backdrop. Roche’s Hemlibra continues to pressure treatments for haemophilia, a blood-clotting disorder, he wrote, while CSL remains the second-largest influenza vaccine maker behind Sanofi. 5
Other March 13 filings were routine, but watched anyway. CSL sought quotation for 167,561 shares issued under its employee plan at A$124.56 each and disclosed 60,048 new restricted rights, including 39,579 granted to Naylor under the long-term incentive plan. 6
The risk for shareholders is that capital returns do not offset a slower operating rebound. Citi said after the February result that CSL’s guidance left little room for error because vaccine unit Seqirus contributes little in the second half, Vifor is still facing generics, and Behring must do “most of the heavy lifting” to hit the year’s targets. That leaves the stock well below its A$275.79 peak of the past 12 months. 4
